| Discovery Services | End-to-end drug discovery including chemistry, biology, DMPK, data analytics and integrated therapeutic research platforms. | Proprietary platforms, skilled scientists, strong client relationships, regulatory accreditations. | Global pharma, biotech firms across multiple therapeutic areas (B2B). | Advanced biology, AI-enabled discovery, and integrated platform services. | 1200 | 33 | Fee-for-service contracts, milestone and outcome-based collaborations. | Mix of competitive pricing and value-driven differentiated services with milestone payments. | Innovation in AI platforms, expanding biotech client base, increasing outsourcing trend. | SynVent™, SARchitect, SynTIPS, Syn.AI |
| Development and Manufacturing Services – Large Molecules | Process development and GMP manufacturing for biologics including monoclonal antibodies, plasmid DNA, mRNA and clinical/commercial supply. | State-of-the-art facilities, geographic diversification, long-term global partnerships. | Pharma and animal health sectors requiring biologics (B2B). | Commercial biologics manufacturing and fill-finish services. | 1400 | 39 | Contract manufacturing and development fees, long-term supply agreements. | Project-based with long-term contracts and capacity utilization fees. | Biologics demand growth, new facility acquisitions (USA), Zoetis partnership. | Biologics CDMO |
| Development and Manufacturing Services – Small Molecules | Drug substance/process development and manufacturing of clinical and commercial batches of APIs and formulations. | Integrated development-manufacturing model, regulatory approvals, strong client pipeline. | Pharmaceutical companies (B2B). | Process R&D and commercial manufacturing. | 620 | 17 | Contract development and manufacturing fees, commercial supply agreements. | Fee-for-service and supply contracts with follow-the-molecule approach. | Operational efficiency improvements, process scale-up, expanded client base of large pharma. | Small Molecule CDMO |
| Dedicated R&D Centres | Exclusive ring-fenced research infrastructure and teams for individual clients providing flexibility and close collaboration. | Customized infrastructure, protected IP environments, integration with client goals. | Large pharma and biotech requiring strategic outsourcing models. | Exclusive long-term partnerships with blue-chip clients. | 420 | 11 | Fixed fee and full-time equivalent charges under long-term contracts. | Long-term contracts with dedicated teams and infrastructure costs recovered. | Increasing demand for dedicated extended collaborations for innovation acceleration. | Exclusive client-dedicated labs |
